One of the world’s leading Covid-19 experimental vaccines produces an immune response in older adults as well as the young, its developers say, raising hopes of protection for those most vulnerable to the coronavirus that has caused social and economic chaos around the world.
Neither Oxford University nor its commercial partner AstraZeneca would release the data from the early trials showing the positive effects, which are being submitted to a peer-reviewed journal. But AstraZeneca confirmed the basic findings about the vaccine it calls AZD1222, which were shared at a closed academic meeting.
The phase 2 trials have shown that people over the age of 56 – and some over 70 – produced the same sort of antibody response as younger volunteers. Whether older people would be protected has always been a key question for the vaccines being developed. The body’s natural immune system and therefore its ability to fight any virus weakens with age, which is why the Covid death rate rises in older people.
The data also show that fewer side-effects – referred to by the scientists as “reactogenicity” – were reported in the older volunteers, which is encouraging, although it could mean that fewer of them reported issues such as a sore arm.
“It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the Covid-19 disease severity is higher. The results further build the body of evidence for the safety and immunogenicity of AZD1222,” said an AstraZeneca spokesman.
A vaccine that works is seen as a game-changer in the battle against coronavirus, which has killed more than 1.15 million people, shuttered swathes of the global economy and turned normal life upside down for billions of people. However, few think the first vaccines will be fully protective. They may instead reduce the severity of illness, so that people avoid hospital and deaths are reduced. They may also not last, so that boosters will be needed.
AstraZeneca said it hoped the vaccine may be ready for limited use within the coming months. “We anticipate efficacy read-outs from phase 2/3 trials between now and the end of the year, and if approved within countries, doses of the potential vaccine could be available for use before the end of the year,” said the spokesperson.
Image Credit: Amanda Scott/ Envato
Post by Amanda Scott, NA CEO. Follow her on twitter @tantriclens
Thanks to Heinz V. Hoenen. Follow him on twitter: @HeinzVHoenen
News
Delta variant of SARS-CoV-2 will likely be dominant strain globally within months
The highly transmissible delta variant of SARS-CoV-2, the coronavirus causing the disease COVID-19, is now present in 124 countries and will become the dominant strain globally in the coming months as it is outcompeting [...]
UK scientists back Covid boosters as study finds post-jab falls in antibodies
Scientists have backed proposals for Covid boosters in the autumn after blood tests on hundreds of people revealed that protective antibodies can wane substantially within weeks of second vaccine shots being given. Falls in [...]
Pfizer-BioNTech and Moderna COVID-19 vaccines establish recall responses to reinfection
Researchers in the United States have conducted a study showing that the coronavirus disease 2019 (COVID-19) vaccines developed by Pfizer-BioNTech and Moderna generate a coordinated adaptive immune response that is capable of eliciting recall [...]
Study shows new ‘warm vaccine’ effective against all key virus variants
CSIRO, Australia's national science agency, played an important role in evaluating heat-tolerant COVID-19 vaccine formulations developed by the Indian Institute of Science (IISc) and biotech start-up Mynvax—against all current SARS-CoV-2 variants of concern. Published [...]
Podcast – Nanovisaging 2040 How Synergies between Nanotechnology, Nanomedicine, and AI might Benefit Humanity
Frank Boehm (NanoApps Medical Inc. Founder) in discussion with Nana Kay in a Wealth Secrets podcast. EP 19. Nanovisaging 2040. From Nana Kay: Nanovisaging 2040: How Synergies between Nanotechnology, Nanomedicine, and AI might Benefit [...]
Data in favour of mixing COVID-19 vaccines, but long-term effects unknown
Canada, like several other countries, has been mixing and matching COVID-19 vaccines for weeks amid safety concerns over the AstraZeneca shot. On Monday, the chief scientist at the World Health Organization (WHO) cautioned against that approach, calling [...]
CRISPR stops coronavirus replication in human cells
Scientists have harnessed CRISPR gene-editing technology to block the replication of the novel coronavirus in human cells — an approach that could one day serve as a new treatment for COVID-19. However, the study was performed [...]
Controlling the Size of Nanoparticles
Depositing nanoparticles using the NL50 is now simpler than ever with the pre-loaded optimized recipes for a variety of frequently used materials, including Au, Ag, Pt and Cu. These optimized recipes generate high-quality nano-coatings [...]
Shape of Nanoparticles in Body Fluids – a Biomarker for Identifying Cancer Types?
A recent study by scientists from Japanese universities has shown that the shape of cell-derived nanoparticles, known as "extracellular vesicles" (EVs), in body fluids could be a biomarker for identifying types of cancer. In [...]
Study reveals how our immune system reacts to COVID-19 variants
An important lesson for vaccine design Australian scientists researching how our immune system responds to COVID-19 have revealed that those infected by early variants in 2020 produced sustained antibodies, however, these antibodies are not [...]
COVID-19: What you need to know about the coronavirus pandemic on 8 July
1. How COVID-19 is affecting the globe Confirmed cases of COVID-19 have passed 185 million globally, according to Johns Hopkins University. The number of confirmed deaths stands at more than 4 million. More than 3.29 [...]
Here’s what you should know about the Lambda variant
The World Health Organization (WHO) has added another COVID strain to its list of coronavirus variants to keep an eye on: the COVID-19 Lambda variant. This particular variant has now spread to more than two dozen [...]
Scientists identify breakthrough cases of SARS-CoV-2’s delta in fully vaccinated individuals
In a recent study conducted at the Baylor College of Medicine, Houston, USA, scientists have identified six vaccine breakthrough cases caused by the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A [...]
‘More dangerous than Delta’: Lambda strain detected in over 30 countries
A new Covid-19 strain that is much more dangerous than the Delta variant has been detected in more than 30 countries in the past four weeks, says the Health Ministry. "The Lambda strain was [...]
Covid ‘perfect storm’ as more patients hit by fungal infections
Weakened lungs and immune systems make people increasingly vulnerable, warn scientists. A rash of cases of a rare “black fungus” infection affecting thousands of critically ill Covid patients in India caused alarm last month. [...]
How a COVID-19 infection changes blood cells in the long run
Using real-time deformability cytometry, researchers at the Max-Planck-Zentrum für Physik und Medizin in Erlangen were able to show for the first time: COVID-19 significantly changes the size and stiffness of red and white blood [...]
